InterVenn

company

About

InterVenn unlocks the glycoproteome using artificial intelligence for the development of transformational healthcare solutions in DX and Rx.

Details

Last Funding Type
Seed
Industries
Biotechnology,Life Science,Medical
Founded date
Mar 1, 2017
Number Of Employee
101 - 250
Operating Status
Active
Legal Name
Venn Biosciences Corp
Also Known As
glycoprox,Venn,GlycoProX Biosciences,Venn Biosciences

InterVenn is a life science company unlocking the value of glycoproteomics—glycosylated proteins which are responsible for driving protein function—for the development of transformational healthcare solutions.

The glycoproteome is a source of life-critical information about human biology that has the potential to improve patient outcomes significantly. Still, it has remained inaccessible due to its vast complexity. InterVenn has pioneered a first-of-its-kind AI-powered platform to decode this layer of biology at a clinically meaningful scale for the first time in history.

The company’s platform can produce a robust pipeline of powerful clinical applications, ranging from early disease screening to diagnostics and, potentially, therapeutics. Its proprietary technology platform is accessible to pharma partners seeking rich biology insights to propel their research and development efforts.

Founded by Nobel Laureate Dr. Carolyn Bertozzi, world-class scientist and distinguished professor Dr. Carlito Lebrilla and leading AI/ML expert & serial entrepreneur Aldo Carrascoso, InterVenn will contribute to making the new era of personalized, predictive, and preventative care a reality.

For more information about InterVenn, visit www.intervenn.com.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
5
$278.08M
InterVenn has raised a total of $278.08M in funding over 2 rounds. Their latest funding was raised on Aug 2, 2021 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 2, 2021 Series C $201M 8 SoftBank Capital Detail
Nov 16, 2020 Series B $34M 6 Anzu Partners Detail
Jul 13, 2020 Series Unknown $33.68M Detail
Dec 12, 2018 Series Unknown $9.40M 5 Genoa Ventures Detail
Apr 1, 2017 Seed 2 Detail

Investors

Number of Lead Investors
Number of Investors
3
13
InterVenn is funded by 13 investors. SoftBank Capital and Amplify Partners are the most recent investors.
Investor Name Lead Investor Funding Round
SoftBank Capital Yes Series C
Amplify Partners Series C
Anzu Partners Series C
Genoa Ventures Series C
Heritage Provider Network Series C
Highside Capital Management Series C
Irving Investors Series C
True Ventures Series C
Ojjeh Family Fund Series B
Xeraya Capital Series B

Employee Profiles

Number of Employee Profiles
23
InterVenn has 23 current employee profiles, including Executive Tillman Pearce
Executive
Executive
Executive
Executive
Executive